Evidence map›Paper›PMID 42443275›Full record

ArticleScientific reports2026

Differential role for hepatic glucuronidation and sulfonation in controlling the 24S-hydroxycholesterol ability to activate LXR.

Valérie Brousseau, Eva Rettenmeier, Mélanie Verreault, Jocelyn Trottier, Shujuan Chen, Robert H Tukey, Olivier Barbier

Abstract read
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Valérie BrousseauLaboratory of Molecular Pharmacology, Endocrinology and Nephrology Axis, CHU de Québec Research Center and the Faculty of Pharmacy, Laval University, 2705 Laurier Boulevard, Québec, QC, G1V 4G2, Canada.
Eva RettenmeierLaboratory of Environmental Toxicology, Department of Pharmacology, University of California San Diego, La Jolla, CA, 92093, USA.
Mélanie VerreaultLaboratory of Molecular Pharmacology, Endocrinology and Nephrology Axis, CHU de Québec Research Center and the Faculty of Pharmacy, Laval University, 2705 Laurier Boulevard, Québec, QC, G1V 4G2, Canada.
Jocelyn TrottierLaboratory of Molecular Pharmacology, Endocrinology and Nephrology Axis, CHU de Québec Research Center and the Faculty of Pharmacy, Laval University, 2705 Laurier Boulevard, Québec, QC, G1V 4G2, Canada.
Shujuan ChenLaboratory of Environmental Toxicology, Department of Pharmacology, University of California San Diego, La Jolla, CA, 92093, USA.
Robert H TukeyLaboratory of Environmental Toxicology, Department of Pharmacology, University of California San Diego, La Jolla, CA, 92093, USA.
Olivier BarbierLaboratory of Molecular Pharmacology, Endocrinology and Nephrology Axis, CHU de Québec Research Center and the Faculty of Pharmacy, Laval University, 2705 Laurier Boulevard, Québec, QC, G1V 4G2, Canada. olivier.barbier@pha.ulaval.ca.

Funding

Natural Sciences and Engineering Research Council of Canada RGPIN-2021-04371
6 · The paper itself

Abstract

24S-hydroxycholesterol (24SOH-Chol) is a bioactive cholesterol metabolite formed in the brain. This endogenous activator of the cholesterol sensor, liver X receptor (LXR) is abundantly found as a sulfate-glucuronide diconjugate in the human plasma. The present study characterizes the human sulfonating (SULT) and glucuronidating (UGT) enzymes; and evaluates how these enzymes impact its ability to bind to and activate LXR. In vitro enzymatic assays identified the human SULT2A1 and UGT1A4 as the major isoforms for hepatic 24SOH-Chol sulfonation and glucuronidation, respectively. Additional assays demonstrated that 24SOH-Chol-3Sulfate,24Glucuronide formation requires the successive involvement of UGT1A4 and SULT2A1. TR-FRET and transient transfection experiments revealed that glucuronidation, but not sulfonation, inactivates 24SOH-Chol. Exposure of human liver cells and humanized UGT1 mice to LXR ligands identified UGT1A4, but not SULT2A1, as a positively regulated LXR target gene, while chromatin immunoprecipitation assays, luciferase reporter and siRNA knock down assays demonstrated the ability of LXR to bind to and activate the human UGT1A4 gene promoter. The present study establishes the complementary roles played by SULT2A1 and UGT1A4 in 24SOH-Chol conjugation. We also identify glucuronidation as a mechanism allowing this cholesterol derivative to self-stimulate its own inactivation.

Identifiers

PMID42443275
PMCPMC13661233

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.